Genedrive MT-RNR1 ID Kit to detect genetic variation and protect hearing in babies: early value appraisal.
The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.
Recent Posts
Inequality-Adjusted ICER: Enhancing Cost-Effectiveness in Health Technology Evaluation
The inequality-adjusted ICER offers a practical way to embed explicit trade-offs between maximising total population health and reducing health inequality directly into cost-effectiveness analysis. By dividing the conventional ICER by an inequality-adjusted ICER, analysts derive a health inequali...
Semaglutide Distribution Flexibility: EMA Approves Room Temperature Delivery for Wegovy®
The European Medicines Agency (EMA) has granted an important update to the product information for Wegovy (semaglutide), introducing semaglutide distribution flexibility that allows controlled-temperature delivery at up to 30°C for up to 48 hours during the final leg from pharmacies to patients. ...
Shift in Portuguese Pediatric Vaccination Policy: Evolving Perspectives on Risk and Benefit
Portuguese Pediatric Vaccination is now restricted to children with specific high-risk conditions, following the exact approach recommended by pharmaceutical experts in 2021. Portuguese health authorities have abandoned universal COVID-19 vaccination for children, limiting the program to those ag...